Total Payments
$944,679
2024 Payments
$320.62
Companies
13
Transactions
26
Medicare Patients
1,135
Medicare Billing
$188,541
Payment Breakdown by Category
Other$943,437 (99.9%)
Food & Beverage$626.55 (0.1%)
Travel$406.06 (0.0%)
Research$191.83 (0.0%)
Education$17.52 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Acquisitions | $943,437 | 3 | 99.9% |
| Food and Beverage | $626.55 | 11 | 0.1% |
| Travel and Lodging | $406.06 | 8 | 0.0% |
| Unspecified | $191.83 | 3 | 0.0% |
| Education | $17.52 | 1 | 0.0% |
Payments by Type
General
$944,487
23 transactions
Research
$191.83
1 transactions
Ownership
$0
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | $943,437 | 5 | $0 (2024) |
| GENZYME CORPORATION | $644.16 | 9 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $191.83 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $96.61 | 1 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $81.96 | 1 | $0 (2024) |
| Genentech, Inc. | $57.41 | 1 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $48.26 | 2 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $26.97 | 1 | $0 (2017) |
| PFIZER INC. | $26.94 | 1 | $0 (2023) |
| Lilly USA, LLC | $25.91 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $320.62 | 4 | Regeneron Pharmaceuticals, Inc. ($191.83) |
| 2023 | $943,509 | 8 | Zimmer Biomet Holdings, Inc. ($943,414) |
| 2020 | $57.41 | 1 | Genentech, Inc. ($57.41) |
| 2019 | $392.25 | 7 | GENZYME CORPORATION ($379.14) |
| 2018 | $372.91 | 5 | GENZYME CORPORATION ($265.02) |
| 2017 | $26.97 | 1 | SANOFI-AVENTIS U.S. LLC ($26.97) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $191.83 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION | ||||||
| 10/04/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $81.96 | General |
| 02/16/2024 | Zimmer Biomet Holdings, Inc. | — | Acquisitions | Cash or cash equivalent | $23.44 | General |
| 09/26/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2023 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $25.91 | General |
| 06/15/2023 | Zimmer Biomet Holdings, Inc. | Tapestry (Device) | Acquisitions | Cash or cash equivalent | $97.06 | General |
| Category: Sports Medicine | ||||||
| 06/08/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $17.52 | General |
| Category: Oncology | ||||||
| 05/23/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: Oncology | ||||||
| 02/14/2023 | Zimmer Biomet Holdings, Inc. | Tapestry (Device) | Acquisitions | Cash or cash equivalent | $943,316.49 | General |
| Category: Sports Medicine | ||||||
| 2023 | Zimmer Biomet Holdings, Inc. | — | — | — | $0.00 | Ownership |
| 2023 | Zimmer Biomet Holdings, Inc. | — | — | — | $0.00 | Ownership |
| 02/14/2020 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $57.41 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $159.79 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $126.84 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $55.67 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $24.00 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $7.20 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $5.64 | General |
| 09/06/2019 | Amgen Inc. | KANJINTI (Biological), Nplate, XGEVA | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: Oncology | ||||||
| 10/26/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $138.23 | General |
| 10/26/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $122.23 | General |
| 10/26/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $4.56 | General |
| 06/03/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA, YONDELIS | Food and Beverage | In-kind items and services | $96.61 | General |
| Category: Oncology | ||||||
| 02/21/2018 | Prometheus Laboratories Inc. | — | Food and Beverage | In-kind items and services | $11.28 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION | Regeneron Pharmaceuticals, Inc. | $191.83 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 282 | 623 | $114,235 | $53,193 |
| 2022 | 3 | 280 | 600 | $103,032 | $49,398 |
| 2021 | 3 | 273 | 596 | $97,000 | $49,032 |
| 2020 | 7 | 300 | 579 | $88,915 | $36,918 |
Total Patients
1,135
Total Services
2,398
Medicare Billing
$188,541
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 88 | 222 | $49,062 | $23,843 | 48.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 143 | 347 | $46,615 | $22,631 | 48.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 40 | 40 | $14,834 | $5,416 | 36.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 14 | $3,724 | $1,303 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 165 | 422 | $56,782 | $27,913 | 49.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 67 | 130 | $28,730 | $14,878 | 51.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 48 | 48 | $17,520 | $6,606 | 37.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 178 | 473 | $63,967 | $34,262 | 53.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 56 | 84 | $18,798 | $9,257 | 49.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 39 | 39 | $14,235 | $5,514 | 38.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 158 | 409 | $55,274 | $23,495 | 42.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 27 | 50 | $11,050 | $4,275 | 38.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 24 | 24 | $8,760 | $3,047 | 34.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 29 | 29 | $7,714 | $2,886 | 37.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 21 | 23 | $2,300 | $1,372 | 59.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 30 | 33 | $1,782 | $1,200 | 67.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 11 | $2,035 | $642.41 | 31.6% |
About Edward Gelmann
Edward Gelmann is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1285632067.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Edward Gelmann has received a total of $944,679 in payments from pharmaceutical and medical device companies, with $320.62 received in 2024. These payments were reported across 26 transactions from 13 companies. The most common payment nature is "Acquisitions" ($943,437).
As a Medicare-enrolled provider, Gelmann has provided services to 1,135 Medicare beneficiaries, totaling 2,398 services with total Medicare billing of $188,541. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 07/14/2005
- Last Updated 10/27/2014
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1285632067
Products in Payments
- Tapestry (Device) $943,414
- NO PRODUCT DISCUSSED (Drug) $671.13
- DARZALEX (Biological) $96.61
- XTANDI (Drug) $26.94
- IMFINZI (Biological) $24.87
- LYNPARZA (Drug) $23.39
- OPDIVO (Biological) $17.52
- KANJINTI (Biological) $13.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Medical Oncology $1.2M
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555
Kevin Kalinsky, M.d, M.D
Medical Oncology — Payments: $471,305
Medical Oncology $471,305